An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases

BMC Molecular Biology

Volumn 13, Issue , 2012, Pages

  Fiszer, Agnieszka ^a   Olejniczak, Marta ^a   Switonski, Pawel M ^a   Wroblewska, Joanna P ^a   Wisniewska Kruk, Joanna ^a   Mykowska, Agnieszka ^a   Krzyzosiak, Wlodzimierz J ^a  

^a INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

Author keywords

Antisense oligonucleotides; Cag repeat targeting; Polyglutamine diseases; Sirna; SNP targeting; Triplet repeats

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; OLIGONUCLEOTIDE; POLYGLUTAMINE; SMALL INTERFERING RNA; ATXN3 PROTEIN, HUMAN; HTT PROTEIN, HUMAN; NERVE PROTEIN; NUCLEAR PROTEIN; REPRESSOR PROTEIN;

ARTICLE; CAG REPEAT; CONTROLLED STUDY; GENE REPLACEMENT THERAPY; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; SINGLE NUCLEOTIDE POLYMORPHISM; SPINOCEREBELLAR DEGENERATION; ALLELE; CELL LINE; DRUG SCREENING; GENE THERAPY; GENETICS; METABOLISM;

ALLELES; CELL LINE; DRUG EVALUATION, PRECLINICAL; GENE SILENCING; GENE THERAPY; HUMANS; HUNTINGTON DISEASE; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; OLIGONUCLEOTIDES; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; SPINOCEREBELLAR ATAXIAS;

EID: 84857721326     PISSN: None     EISSN: 14712199     Source Type: Journal    
DOI: 10.1186/1471-2199-13-6     Document Type: Article

References (68)

1. Orr HT, Zoghbi HY. Trinucleotide repeat disorders. Annu Rev Neurosci 2007, 30:575-621. 10.1146/annurev.neuro.29.051605.113042, 17417937.
2. Koshy BT, Zoghbi HY. The CAG/polyglutamine tract diseases: gene products and molecular pathogenesis. Brain Pathol 1997, 7(3):927-942. 10.1111/j.1750-3639.1997.tb00894.x, 9217976.
3. Williams AJ, Paulson HL. Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci 2008, 31(10):521-528. 10.1016/j.tins.2008.07.004, 2580745, 18778858.
4. La Spada AR, Taylor JP. Repeat expansion disease: progress and puzzles in disease pathogenesis. Nat Rev Genet 2010, 11(4):247-258. 10.1038/nrg2748, 20177426.
5. Li LB, Yu Z, Teng X, Bonini NM. RNA toxicity is a component of ataxin-3 degeneration in Drosophila. Nature 2008, 453(7198):1107-1111. 10.1038/nature06909, 2574630, 18449188.
6. Mykowska A, Sobczak K, Wojciechowska M, Kozlowski P, Krzyzosiak WJ. CAG repeats mimic CUG repeats in the misregulation of alternative splicing. Nucleic Acids Res 2011, 39(20):8938-8951. 10.1093/nar/gkr608, 3203611, 21795378.
7. Shieh SY, Bonini NM. Genes and pathways affected by CAG-repeat RNA-based toxicity in Drosophila. Hum Mol Genet 2011, 20(24):4810-4821. 10.1093/hmg/ddr420, 3221540, 21933837.
8. Hsu RJ, Hsiao KM, Lin MJ, Li CY, Wang LC, Chen LK, Pan H. Long tract of untranslated CAG repeats is deleterious in transgenic mice. PLoS One 2011, 6(1):16417.
9. Davidson BL, McCray PB. Current prospects for RNA interference-based therapies. Nat Rev Genet 2011, 12(5):329-340. 10.1038/nrg2968, 21499294.
10. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411(6836):494-498. 10.1038/35078107, 11373684.
11. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002, 16(8):948-958. 10.1101/gad.981002, 152352, 11959843.
12. Alves S, Nascimento-Ferreira I, Dufour N, Hassig R, Auregan G, Nobrega C, Brouillet E, Hantraye P, Pedroso de Lima MC, Deglon N, et al. Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3?. Hum Mol Genet 2010, 19(12):2380-2394. 10.1093/hmg/ddq111, 20308049.
13. Boudreau RL, McBride JL, Martins I, Shen S, Xing Y, Carter BJ, Davidson BL. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther 2009, 17(6):1053-1063. 10.1038/mt.2009.17, 2835182, 19240687.
14. Drouet V, Perrin V, Hassig R, Dufour N, Auregan G, Alves S, Bonvento G, Brouillet E, Luthi-Carter R, Hantraye P, et al. Sustained effects of nonallele-specific Huntingtin silencing. Ann Neurol 2009, 65(3):276-285. 10.1002/ana.21569, 19334076.
15. McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, Martins I, Gilmore BL, Burstein H, Peluso RW, Polisky B, et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 2008, 105(15):5868-5873. 10.1073/pnas.0801775105, 2311380, 18398004.
16. Lim J, Crespo-Barreto J, Jafar-Nejad P, Bowman AB, Richman R, Hill DE, Orr HT, Zoghbi HY. Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature 2008, 452(7188):713-718. 10.1038/nature06731, 2377396, 18337722.
17. White JK, Auerbach W, Duyao MP, Vonsattel JP, Gusella JF, Joyner AL, MacDonald ME. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat Genet 1997, 17(4):404-410. 10.1038/ng1297-404, 9398841.
18. Dragatsis I, Levine MS, Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 2000, 26(3):300-306. 10.1038/81593, 11062468.
19. Carroll JB, Warby SC, Southwell AL, Doty CN, Greenlee S, Skotte N, Hung G, Bennett CF, Freier SM, Hayden MR. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the huntington disease gene/allele-specific silencing of mutant huntingtin. Mol Ther 2011, 19(12):2178-2185. 10.1038/mt.2011.201, 21971427.
20. Pfister EL, Kennington L, Straubhaar J, Wagh S, Liu W, DiFiglia M, Landwehrmeyer B, Vonsattel JP, Zamore PD, Aronin N. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol 2009, 19(9):774-778. 10.1016/j.cub.2009.03.030, 2746439, 19361997.
21. Schwarz DS, Ding H, Kennington L, Moore JT, Schelter J, Burchard J, Linsley PS, Aronin N, Xu Z, Zamore PD. Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet 2006, 2(9):e140. 10.1371/journal.pgen.0020140, 1560399, 16965178.
22. Takahashi M, Watanabe S, Murata M, Furuya H, Kanazawa I, Wada K, Hohjoh H. Tailor-made RNAi knockdown against triplet repeat disease-causing alleles. Proc Natl Acad Sci USA 2010, 107(50):21731-21736. 10.1073/pnas.1012153107, 3003091, 21098280.
23. van Bilsen PH, Jaspers L, Lombardi MS, Odekerken JC, Burright EN, Kaemmerer WF. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts. Hum Gene Ther 2008, 19(7):710-719. 10.1089/hum.2007.116, 18549309.
24. Alves S, Nascimento-Ferreira I, Auregan G, Hassig R, Dufour N, Brouillet E, Pedroso de Lima MC, Hantraye P, Pereira de Almeida L, Deglon N. Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. PLoS One 2008, 3(10):e3341. 10.1371/journal.pone.0003341, 2553199, 18841197.
25. Li Y, Yokota T, Matsumura R, Taira K, Mizusawa H. Sequence-dependent and independent inhibition specific for mutant ataxin-3 by small interfering RNA. Ann Neurol 2004, 56(1):124-129. 10.1002/ana.20141, 15236410.
26. Miller VM, Xia H, Marrs GL, Gouvion CM, Lee G, Davidson BL, Paulson HL. Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci USA 2003, 100(12):7195-7200. 10.1073/pnas.1231012100, 165852, 12782788.
27. Scholefield J, Greenberg LJ, Weinberg MS, Arbuthnot PB, Abdelgany A, Wood MJ. Design of RNAi hairpins for mutation-specific silencing of ataxin-7 and correction of a SCA7 phenotype. PLoS One 2009, 4(9):e7232. 10.1371/journal.pone.0007232, 2747278, 19789634.
28. Lombardi MS, Jaspers L, Spronkmans C, Gellera C, Taroni F, Di Maria E, Donato SD, Kaemmerer WF. A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exp Neurol 2009, 217(2):312-319. 10.1016/j.expneurol.2009.03.004, 19289118.
29. Warby SC, Montpetit A, Hayden AR, Carroll JB, Butland SL, Visscher H, Collins JA, Semaka A, Hudson TJ, Hayden MR. CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. Am J Hum Genet 2009, 84(3):351-366. 10.1016/j.ajhg.2009.02.003, 2668007, 19249009.
30. Fiszer A, Mykowska A, Krzyzosiak WJ. Inhibition of mutant huntingtin expression by RNA duplex targeting expanded CAG repeats. Nucleic Acids Res 2011, 39(13):5578-5585. 10.1093/nar/gkr156, 3141264, 21427085.
31. Hu J, Matsui M, Corey DR. Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA. Ann N Y Acad Sci 2009, 1175:24-31. 10.1111/j.1749-6632.2009.04975.x, 19796074.
32. Hu J, Matsui M, Gagnon KT, Schwartz JC, Gabillet S, Arar K, Wu J, Bezprozvanny I, Corey DR. Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol 2009, 27(5):478-484. 10.1038/nbt.1539, 2765218, 19412185.
33. Hu J, Liu J, Corey DR. Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism. Chem Biol 2010, 17(11):1183-1188. 10.1016/j.chembiol.2010.10.013, 3021381, 21095568.
34. Wang YL, Liu W, Wada E, Murata M, Wada K, Kanazawa I. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. Neurosci Res 2005, 53(3):241-249. 10.1016/j.neures.2005.06.021, 16095740.
35. DiFiglia M, Sena-Esteves M, Chase K, Sapp E, Pfister E, Sass M, Yoder J, Reeves P, Pandey RK, Rajeev KG, et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci USA 2007, 104(43):17204-17209. 10.1073/pnas.0708285104, 2040405, 17940007.
36. Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q, Yang L, Kotin RM, Paulson HL, Davidson BL. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA 2005, 102(16):5820-5825. 10.1073/pnas.0501507102, 556303, 15811941.
37. Rodriguez-Lebron E, Denovan-Wright EM, Nash K, Lewin AS, Mandel RJ. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol Ther 2005, 12(4):618-633. 10.1016/j.ymthe.2005.05.006, 2656966, 16019264.
38. Stiles D, Zhang Z, Ge P, Nelson B, Grondin R, Ai Y, Hardy P, Nelson PT, Guzaev AP, Butt MT, et al. Widespread suppression of huntingtin with convection-enhanced delivery of siRNA. Exp Neurol 2011, doi:10.1016/j.expneurol.2011.11.020.
39. Kubodera T, Yamada H, Anzai M, Ohira S, Yokota S, Hirai Y, Mochizuki H, Shimada T, Mitani T, Mizusawa H, et al. In vivo application of an RNAi strategy for the selective suppression of a mutant allele. Hum Gene Ther 2011, 22(1):27-34. 10.1089/hum.2010.054, 20649474.
40. Kubodera T, Yokota T, Ishikawa K, Mizusawa H. New RNAi strategy for selective suppression of a mutant allele in polyglutamine disease. Oligonucleotides 2005, 15(4):298-302. 10.1089/oli.2005.15.298, 16396623.
41. Xia XG, Zhou H, Zhou S, Yu Y, Wu R, Xu Z. An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu, Zn superoxide dismutase. J Neurochem 2005, 92(2):362-367. 10.1111/j.1471-4159.2004.02860.x, 15663483.
42. Kiang AS, Palfi A, Ader M, Kenna PF, Millington-Ward S, Clark G, Kennan A, O'Reilly M, Tam LC, Aherne A, et al. Toward a gene therapy for dominant disease: validation of an RNA interference-based mutation-independent approach. Mol Ther 2005, 12(3):555-561. 10.1016/j.ymthe.2005.03.028, 15967729.
43. O'Reilly M, Palfi A, Chadderton N, Millington-Ward S, Ader M, Cronin T, Tuohy T, Auricchio A, Hildinger M, Tivnan A, et al. RNA interference-mediated suppression and replacement of human rhodopsin in vivo. Am J Hum Genet 2007, 81(1):127-135. 10.1086/519025, 1950918, 17564969.
44. Du Q, Thonberg H, Wang J, Wahlestedt C, Liang Z. A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites. Nucleic Acids Res 2005, 33(5):1671-1677. 10.1093/nar/gki312, 1069010, 15781493.
45. Huang H, Qiao R, Zhao D, Zhang T, Li Y, Yi F, Lai F, Hong J, Ding X, Yang Z, et al. Profiling of mismatch discrimination in RNAi enabled rational design of allele-specific siRNAs. Nucleic Acids Res 2009, 37(22):7560-7569. 10.1093/nar/gkp835, 2794185, 19815667.
46. Chang CI, Kim HA, Dua P, Kim S, Li CJ, Lee DK. Structural diversity repertoire of gene silencing small interfering RNAs. Nucleic Acid Ther 2011, 21(3):125-131. 3198623, 21749289.
47. Patrick Walton S, Wu M, Gredell JA, Chan C. Designing highly active siRNAs for therapeutic applications. FEBS J 2010, 277(23):4806-4813. 10.1111/j.1742-4658.2010.07903.x, 3052974, 21078115.
48. Bramsen JB, Laursen MB, Damgaard CK, Lena SW, Babu BR, Wengel J, Kjems J. Improved silencing properties using small internally segmented interfering RNAs. Nucleic Acids Res 2007, 35(17):5886-5897. 10.1093/nar/gkm548, 2034465, 17726057.
49. Dua P, Yoo JW, Kim S, Lee DK. Modified siRNA structure with a single nucleotide bulge overcomes conventional siRNA-mediated off-target silencing. Mol Ther 2011, 19(9):1676-1687. 10.1038/mt.2011.109, 21673662.
50. Hohjoh H. Enhancement of RNAi activity by improved siRNA duplexes. FEBS Lett 2004, 557(1-3):193-198. 10.1016/S0014-5793(03)01492-3, 14741366.
51. Sun X, Rogoff HA, Li CJ. Asymmetric RNA duplexes mediate RNA interference in mammalian cells. Nat Biotechnol 2008, 26(12):1379-1382. 10.1038/nbt.1512, 19029911.
52. Chang CI, Yoo JW, Hong SW, Lee SE, Kang HS, Sun X, Rogoff HA, Ban C, Kim S, Li CJ, et al. Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects. Mol Ther 2009, 17(4):725-732. 10.1038/mt.2008.298, 2835116, 19156133.
53. Bramsen JB, Laursen MB, Nielsen AF, Hansen TB, Bus C, Langkjaer N, Babu BR, Hojland T, Abramov M, Van Aerschot A, et al. A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res 2009, 37(9):2867-2881. 10.1093/nar/gkp106, 2685080, 19282453.
54. Michlewski G, Krzyzosiak WJ. Molecular architecture of CAG repeats in human disease related transcripts. J Mol Biol 2004, 340(4):665-679. 10.1016/j.jmb.2004.05.021, 15223312.
55. Gaspar C, Lopes-Cendes I, Hayes S, Goto J, Arvidsson K, Dias A, Silveira I, Maciel P, Coutinho P, Lima M, et al. Ancestral origins of the Machado-Joseph disease mutation: a worldwide haplotype study. Am J Hum Genet 2001, 68(2):523-528. 10.1086/318184, 1235286, 11133357.
56. Starega-Roslan J, Krol J, Koscianska E, Kozlowski P, Szlachcic WJ, Sobczak K, Krzyzosiak WJ. Structural basis of microRNA length variety. Nucleic Acids Res 2011, 39(1):257-268. 10.1093/nar/gkq727, 3017592, 20739353.
57. Koscianska E, Starega-Roslan J, Sznajder LJ, Olejniczak M, Galka-Marciniak P, Krzyzosiak WJ. Northern blotting analysis of microRNAs, their precursors and RNA interference triggers. BMC Mol Biol 2011, 12:14. 10.1186/1471-2199-12-14, 3080303, 21481235.
58. Kozlowski P, de Mezer M, Krzyzosiak WJ. Trinucleotide repeats in human genome and exome. Nucleic Acids Res 2010, 38(12):4027-4039. 10.1093/nar/gkq127, 2896521, 20215431.
59. Caplen NJ, Taylor JP, Statham VS, Tanaka F, Fire A, Morgan RA. Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference. Hum Mol Genet 2002, 11(2):175-184. 10.1093/hmg/11.2.175, 11809726.
60. Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT, Paulson HL, Yang L, Kotin RM, Davidson BL. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 2004, 10(8):816-820. 10.1038/nm1076, 15235598.
61. Nimesh S, Gupta N, Chandra R. Cationic polymer based nanocarriers for delivery of therapeutic nucleic acids. J Biomed Nanotechnol 2011, 7(4):504-520. 10.1166/jbn.2011.1313, 21870455.
62. de Mezer M, Wojciechowska M, Napierala M, Sobczak K, Krzyzosiak WJ. Mutant CAG repeats of Huntingtin transcript fold into hairpins, form nuclear foci and are targets for RNA interference. Nucleic Acids Res 2011, 39(9):3852-3863. 10.1093/nar/gkq1323, 3089464, 21247881.
63. Chi SW, Zang JB, Mele A, Darnell RB. Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature 2009, 460(7254):479-486. 2733940, 19536157.
64. Broderick JA, Salomon WE, Ryder SP, Aronin N, Zamore PD. Argonaute protein identity and pairing geometry determine cooperativity in mammalian RNA silencing. RNA 2011, 17(10):1858-1869. 10.1261/rna.2778911, 3185918, 21878547.
65. Doench JG, Petersen CP, Sharp PA. siRNAs can function as miRNAs. Genes Dev 2003, 17(4):438-442. 10.1101/gad.1064703, 195999, 12600936.
66. Saetrom P, Heale BS, Snove O, Aagaard L, Alluin J, Rossi JJ. Distance constraints between microRNA target sites dictate efficacy and cooperativity. Nucleic Acids Res 2007, 35(7):2333-2342. 10.1093/nar/gkm133, 1874663, 17389647.
67. Wojciechowska M, Krzyzosiak WJ. CAG repeat RNA as an auxiliary toxic agent in polyglutamine disorders. RNA Biol 2011, 8(4):565-571. 10.4161/rna.8.4.15397, 3225975, 21593608.
68. Krzyzosiak WJ, Sobczak K, Wojciechowska M, Fiszer A, Mykowska A, Kozlowski P. Triplet repeat RNA structure and its role as pathogenic agent and therapeutic target. Nucleic Acids Res 2012, 40(1):11-26. 10.1093/nar/gkr729, 3245940, 21908410.